Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancer
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04096-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Nilesh U Deshpande und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1120 NW 14th Street | Suite 410, Miami, …. Hauptthemen laut MEDLINE: Myeloid-Derived Suppressor Cells, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Nanoparticles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, U.S. Department of Defense.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is characterized by intratumoral abundance of neutrophilic/polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) which exert anti-T-cell functions through multiple mechanisms, especially JAK2/STAT3-regulated arginase activity. To overcome limitations of systemic inhibition of PMN-MDSCs in cancer-bearing patients such as neutropenia and compensatory myelopoietic adaptations, we developed a nanoengineering strategy to disrupt cell-specific signaling exclusively in PMN-MDSCs without compromising viability or provoking neutropenia. Single-cell RNA sequencing in human/murine PDAC, and flow cytometry in peripheral blood cells from treatment-naïve PDAC patients, nominated surface receptor CXCR2 as a PMN-MDSC-exclusive target. We chemically modified a small-molecule CXCR2 inhibitor AZD5069 by conjugating it with polyethylene glycol (PEG) to enhance aqueous solubility. This AZD5069-PEG construct was then chemically grafted onto amphiphilic polysaccharide derivatives to engineer CXCR2-homing nanoparticles (CXCR2-NP). Cy5.5 dye-loaded CXCR2-NPs showed near-exclusive uptake in PMN-MDSCs compared with KrasLSL.G12D/+;p53R172H/+;Pdx1Cre/+ (KPC) PDAC tumor cells, KPC cancer-associated fibroblasts, macrophages, and dendritic cells. Encapsulation of JAK2/STAT3i Ruxolitinib (CXCR2-NPRuxo) resulted in more efficient and durable attenuation in STAT3-regulated arginase activity from PMN-MDSCs as well as robust induction of cytolytic T-cell activity compared with free Ruxolitinib in vitro and in orthotopic tumor cell-CAF co-injection models in vivo. Treatment of orthotopic tumor-bearing KPC mice with CXCR2-NPRuxo reduced tumor burden compared with vehicle, free Ruxolitinib, or non-drug-loaded CXCR2-NP treatments, without causing appreciable neutropenia. Taken together, cell-specific delivery of payloads via CXCR2-homing immunonanoparticles represents a novel strategy to disrupt MDSC-mediated immunosuppression and invigorate antitumor immunity in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1120 NW 14th Street | Suite 410, Miami, FL, 33136, USA.
- Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA.
- Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA.
- Engineering Cancer Cures™ Program, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
- Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1120 NW 14th Street | Suite 410, Miami, FL, 33136, USA. jash.datta@med.miami.edu.
- Sylvester Comprehensive Cancer Center, Sylvester Pancreatic Cancer Research Institute, Miami, FL, USA. jash.datta@med.miami.edu.
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- U.S. Department of Defense
- Pancreatic Cancer Action Network
Zitieren
APA
Deshpande, N. U., Bianchi, A., Amirian, H., De Castro Silva, I., Rafie, C. I., Surnar, B., Rajkumar, K., Ashokan, A., Ogobuiro, I. C., Patel, M., Stelekati, E., Dhar, S., & Datta, J. (2025). Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04096-y
Vancouver
Deshpande NU, Bianchi A, Amirian H, De Castro Silva I, Rafie CI, Surnar B, et al. Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04096-y
BibTeX
@article{Deshpande2025,
author = {Deshpande, Nilesh U and Bianchi, Anna and Amirian, Haleh and De Castro Silva, Iago and Rafie, Christine I and Surnar, Bapurao and Rajkumar, Karthik and Ashokan, Akash and Ogobuiro, Ifeanyichukwu C and Patel, Manan and Stelekati, Erietta and Dhar, Shanta and Datta, Jashodeep},
title = {Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04096-y}
}
EUVIMED